At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,852 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation
In Brief
An observational study for Atrial Fibrillation. Completed, enrolled 1,852 participants across 148 sites in 7 countries.
Detailed Summary
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesBelgium, Denmark, Greece, Netherlands, Norway, Portugal, Sweden
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartNov 2015
Primary CompletionJan 2017
TodayJul 2026
First PostedNov 5, 2015
Enrollment StartNov 11, 2015
Primary CompletionJan 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.7 years ago